NDAORALCAPSULE, DELAYED REL PELLETS
Approved
Jan 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
ERYC (erythromycin) by Dr. Reddy's Laboratories is mechanism of action erythromycin acts by inhibition of protein synthesis by binding 50 s ribosomal subunits of susceptible organisms. First approved in 1981.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERYC is an oral macrolide antibiotic containing erythromycin that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is active against a broad spectrum of gram-positive and gram-negative bacteria, atypical organisms, and some parasites. The delayed-release capsule formulation improves tolerability by reducing gastrointestinal side effects.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial teams are likely focused on maximizing remaining market share and managing generic transition.
Mechanism of Action
Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Resistance The major route of resistance is modification of the 23S rRNA in the 50S ribosomal subunit to insensitivity,…
Pharmacologic Class:
Macrolide
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
Started May 2025
49 enrolled
Healthy Participants
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
Started Apr 2025
20 enrolled
Healthy
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
Started Mar 2024
24 enrolled
Chronic Obstructive Pulmonary Disease
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Started Mar 2024
140 enrolled
Premature Rupture of Membrane
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
Started Feb 2022
16 enrolled
Amyotrophic Lateral SclerosisHealthy Volunteer
Worked on ERYC at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.